What Is Menopause Laser Treatment and Why Are Women Considering It?
vaginal dryness, burning, itching, painful sex, and recurrent urinary tract infections — the constellation of symptoms called genitourinary syndrome of menopause (GSM) affects up to 50 percent of postmenopausal women. Standard treatment is low-dose vaginal estrogen, which works well for most women. But for women who cannot take estrogen — breast cancer survivors on aromatase inhibitors, women with estrogen-sensitive conditions, or women who simply prefer a non-hormonal approach — laser therapy has emerged as an alternative. The pitch is seductive: three quick outpatient sessions, no daily cream, no hormones, and results that last a year or more.
Menopause laser treatment uses fractional CO2 or erbium YAG lasers to deliver microscopic columns of thermal energy to the vaginal lining. The idea is that this controlled injury triggers neocollagenesis, neovascularization, and rejuvenation of the vaginal epithelium — essentially making the tissue thicker, more elastic, and better lubricated. The concept is borrowed from facial skin resurfacing, applied to a very different type of tissue. Whether the vaginal mucosa responds the same way to laser energy as facial skin is the central question that trials are trying to answer.
The FDA has not cleared any laser device specifically for vaginal “rejuvenation” or GSM treatment. In July 2018, the FDA issued a warning about the use of energy-based devices for vaginal cosmetic procedures, stating that “the safety and effectiveness of these devices for these indications have not been established.” Despite this, clinics across the United States continue to offer laser therapy for GSM. The menopause treatment landscape around laser therapy is confusing because the device manufacturers fund most of the published studies, creating an evidence base that is skewed toward positive results.
What the 2025 Clinical Trials Actually Show
The evidence picture changed in 2025 with the publication of two important studies. The first was a double-blind randomized controlled trial published in Climacteric in June 2025 — one of the first properly blinded trials in this space. The study enrolled 85 postmenopausal women with moderate-to-severe GSM symptoms. Half received three fractional CO2 laser sessions at monthly intervals; the other half received a sham procedure using a placebo handpiece that looked and sounded identical. At three months, both groups reported significant improvement in vaginal dryness scores — and the improvement was the same in both groups (about 2.5 points on the 10-point VAS scale). The sham group improved just as much as the laser group. The authors concluded that the early benefit of CO2 laser treatment for GSM is likely driven by a placebo response.
The second study, published in Healthcare (MDPI) in 2024, took a different approach. It measured objective changes in vaginal tissue after CO2 laser treatment, including histology, pH, and the vaginal maturation index. The study found statistically significant improvements in these objective markers after three sessions — increased epithelial thickness from 0.12 mm to 0.19 mm, decreased pH from 5.8 to 4.6, and a shift in cell populations toward superficial cells. The study did not include a sham control group, so the placebo effect could not be separated from the biological effect. But the objective tissue changes suggest that laser therapy does something — the question is whether that something translates into clinically meaningful symptom relief beyond what women experience from a sham procedure.
The extension phase of the 2025 Climacteric trial, published in the same journal later in 2025, offered participants from the blinded study an open-label course of repeat CO2 laser after unblinding. Women who received active treatment in the original trial and then had a second course reported sustained symptom improvement at 12 months. Women who crossed over from sham to active treatment also improved. But the open-label design means the improvements could still be driven by expectation effects. The complete guide to menopause treatment options includes a section on GSM treatments that puts laser therapy in context with all available approaches.
How Laser Compares to Vaginal Estrogen
The comparison that matters for most women is laser versus vaginal estrogen, not laser versus placebo. A 2025 systematic review and meta-analysis in the Journal of Obstetrics and Gynecology directly compared CO2 laser and topical estrogen across six randomized trials with a total of 487 women. The key finding: both treatments were effective, and there was no statistically significant difference between them for most GSM symptoms at the 6-month mark. Vaginal estrogen improved dryness scores by 3.2 points on a 10-point scale; laser improved them by 3.0 points. The difference of 0.2 points is clinically meaningless.
The cost difference, however, is not. Vaginal estrogen costs 30 to 60 dollars per month — around 400 to 700 dollars per year. A course of three laser sessions costs 2,500 to 5,000 dollars and is rarely covered by insurance. Medicare does not cover laser for GSM. Most private insurance plans classify it as cosmetic. If both treatments produce equivalent results at 6 months, the economic argument overwhelmingly favors estrogen. The argument for laser is for women who need a non-hormonal option — specifically breast cancer survivors on aromatase inhibitors, for whom vaginal estrogen, even low-dose, carries theoretical risks that some oncologists prefer to avoid.
The durability question is unresolved. Vaginal estrogen needs to be used indefinitely — maintenance dosing two to three times per week after the initial daily loading phase. Laser proponents claim results last 12 to 18 months, but the evidence for this claim comes from uncontrolled studies with high loss to follow-up. The longest published follow-up is 24 months, from a 2024 open-label Italian study of 108 women, which reported that 62 percent of women still had symptom improvement at 2 years after a single three-session course. That is promising but not definitive. The hormone replacement therapy guide covers the full range of estrogen products and explains how vaginal estrogen differs from systemic HRT in absorption and safety.
Who Should and Should Not Consider Laser Therapy
Laser therapy has a specific place in the GSM treatment algorithm. The best candidates are women who have tried and failed vaginal estrogen — either because of inadequate symptom relief, irritation from the cream base, or personal preference against hormones. Breast cancer survivors are the largest group where laser makes the most sense clinically. A 2025 NAMS expert consensus statement on GSM management in breast cancer patients recommends laser therapy as a second-line non-hormonal option after vaginal moisturizers and lubricants, noting that “the available evidence, while limited, supports safety in this population with no reported cases of estrogen-related cancer recurrence.”
Women who should not seek laser therapy include those with active pelvic infections, vaginal prolapse beyond stage 2, current radiation therapy to the pelvis, or a history of pelvic surgery that altered vaginal anatomy. The procedure is not recommended during pregnancy or breastfeeding for obvious reasons, and it should not be performed during active genitourinary infections. The most common side effects are temporary — mild discomfort, swelling, and discharge for 2 to 5 days after each session. Serious complications like infection, scarring, or fistula formation are rare but have been reported in case series.
The biggest risk in the laser space is predatory marketing. Many clinics advertising “laser vaginal rejuvenation” or “designer vagina” procedures are targeting cosmetic concerns, not medical GSM treatment. The distinction matters because the cosmetic-focused clinics may not have gynecologists on staff, may not screen for contraindications, and may quote prices that do not include follow-up care. A 2025 American College of Obstetricians and Gynecologists committee opinion advises women to confirm that their provider is a board-certified gynecologist or urogynecologist with specific training in GSM laser therapy.
Costs, Sessions, and What to Expect
A standard course of CO2 fractional laser for GSM involves three sessions spaced four to six weeks apart. Each session takes 10 to 15 minutes in the exam room. No anesthesia is typically required, though some clinics offer a topical lidocaine gel. After the procedure, women can resume normal activities immediately but should avoid sexual intercourse and tampon use for 5 to 7 days after each session. The full cost for a three-session course ranges from 2,500 to 5,000 dollars in major US metropolitan areas. A single maintenance session every 12 to 18 months adds 800 to 1,500 dollars.
Erbium YAG laser is an alternative technology that uses a different wavelength (2940 nm versus 10,600 nm for CO2). The erbium laser penetrates less deeply and generates less thermal spread, which means less downtime but potentially less collagen stimulation. A 2025 head-to-head trial of CO2 versus erbium YAG is underway at the Cleveland Clinic, with results expected in 2027. For now, the evidence base is more robust for CO2 laser, but erbium proponents argue it is safer for the thinner, more delicate vaginal tissue of postmenopausal women.
If you are considering laser therapy, the practical checklist is short. Ask the clinic for their complication rate. Ask whether they track patient outcomes at 6 and 12 months. Ask whether you can speak to a patient who had the procedure six months ago. If they cannot provide any of these, find another clinic. The menopause symptoms guide has a GSM-focused section that walks through the full range of treatment options — moisturizers, lubricants, vaginal estrogen, ospemifene, and laser — ranked by strength of evidence, so you can compare apples to apples instead of clinic marketing to clinic marketing.